Russia Unveils Cancer Vaccine After Successful Trials

The Federal Medical and Biological Agency (FMBA) has announced that a new cancer vaccine created by Russian scientists is now prepared for clinical use. Russian news agency TASS reported that FMBA head Veronika Skvortsova announced at the Eastern Economic Forum.

The Enteromix vaccine is based on mRNA technology, which is also the basis for some COVID-19 vaccines. mRNA vaccines instruct the body's cells to produce proteins that initiate an immune response against cancer cells, as opposed to employing a weakened virus.

According to Skvortsova, the vaccine has finished years of research, including the necessary three-year preclinical trials. The results of the trials demonstrated the vaccine's high effectiveness and safety even after repeated doses. Depending on the type of cancer, tumors may shrink or grow more slowly by 60% to 80%. Improved test-subject survival rates were also observed by researchers.

“The research spanned several years, with the last three dedicated to mandatory preclinical studies".

This vaccine will initially target colorectal cancer, also known as large intestine cancer. Vaccines against glioblastoma, a rapidly spreading brain cancer, and some forms of melanoma, a dangerous skin cancer that affects the eye, including ocular melanoma, are also being developed. The announcement was made at the 10th Eastern Economic Forum in Vladivostok, which attracted over 8,400 people from more than 75 nations.

Russia's trial news is worth watching, and EnteroMix is an interesting example of oncolytic-virus and vaccine-style cancer research. However, preclinical findings and Phase I safety data are not equivalent to validated treatments. The responsible message for patients and the general public is that before promising early science can be referred to as a breakthrough treatment, it must undergo independent peer review and larger, controlled trials.

#Enteromix #mRNA #cancervaccine #RussiaScience #ClinicalTrials